QURE — uniQure N.V.

Summary of uniQure N.V. Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $3.7 million for Q3 2025, up from $2.3 million in Q3 2024, primarily due to a $1.5 million increase in license revenues.
• Research and Development Expenses: Increased to $34.4 million from $30.6 million year-over-year, driven by preparations for the BLA submission of AMT-130.
• Selling, General, and Administrative Expenses: Rose to $19.4 million from $11.6 million, largely due to increased employee-related expenses and professional fees.
• Cash Position: Cash, cash equivalents, and investment securities totaled $649.2 million as of September 30, 2025, up from $376.5 million at the end of 2024, providing sufficient runway into 2029.

2. Strategic Updates and Business Highlights

• AMT-130 for Huntington's Disease: Positive top-line data from the pivotal Phase 1/2 study showing a 75% slowing of disease progression. However, the FDA indicated that the data may not be sufficient for a BLA submission, introducing uncertainty.
• AMT-260 for Mesial Temporal Lobe Epilepsy: Initial positive data reported, with 17 recruiting sites activated and a second cohort initiated.
• AMT-191 for Fabry Disease: Encouraging results from the ongoing Phase 1/2a trial, with patients showing stable enzyme activity.
• AMT-162 for SOD1 ALS: Enrollment paused due to a serious adverse event related to dose-limiting toxicity observed in one patient.

3. Forward Guidance and Outlook

• uniQure is focused on engaging with the FDA to clarify the path forward for AMT-130 and remains committed to exploring regulatory pathways in the EU and UK.
• The company plans to publish comprehensive data results in a peer-reviewed journal and is preparing for potential commercialization of AMT-130.

4. Bad News, Challenges, or Points of Concern

• FDA Feedback: The FDA's unexpected stance on the adequacy of AMT-130's data for BLA submission has created uncertainty regarding the timeline for potential approval.
• AMT-162 Trial Concerns: The pause in enrollment due to safety concerns raises questions about the viability of this program.
• Market Sentiment: The emotional impact on the Huntington's disease community following the FDA's feedback could affect stakeholder confidence.

5. Notable Q&A Insights

• Data Robustness: Management emphasized the rigorous methodology used in constructing the external control arm for AMT-130, asserting confidence in the robustness of the data.
• Regulatory Engagement: There is a strong commitment to collaborate with the FDA to address concerns and expedite the BLA submission process.
• Community Support: The patient and physician community remains highly motivated, expressing hope for AMT-130 despite recent setbacks.
• Future Steps: Management is focused on understanding the FDA's concerns and determining how to address them effectively in future discussions.

Overall, while uniQure has made significant progress in its clinical trials, the recent FDA feedback presents a substantial challenge that the company must navigate carefully.